Sorrento Therapeutics, Inc.
GPTKB entity
Properties (48)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
gptkb:Cure_Pharmaceutical_Holding_Corp.
Virttu Biologics |
| gptkbp:awards |
various industry awards
|
| gptkbp:CEO |
gptkb:Henry_Ji
|
| gptkbp:clinicalTrials |
Phase 1
Phase 2 Phase 3 autoimmune diseases infectious diseases cancer therapies pain management therapies therapeutics for COVID-19 therapeutics for cancer therapeutics for chronic pain pain relief products COVID-19_treatment |
| gptkbp:collaborations |
multiple pharmaceutical companies
|
| gptkbp:communityPartnerships |
various academic institutions
|
| gptkbp:employees |
over 100
|
| gptkbp:focus |
oncology
immunotherapy pain management |
| gptkbp:founded |
2006
|
| gptkbp:founder |
gptkb:Henry_Ji
|
| gptkbp:headquarters |
gptkb:San_Diego,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sorrento Therapeutics, Inc.
|
| gptkbp:investmentFocus |
institutional investors
retail investors |
| gptkbp:leads |
ZyCoV-D
COVI-SHIELD COVI-MAB COVI-TEST COVI-TRACK |
| gptkbp:market |
approximately $500 million (2021)
|
| gptkbp:netIncome |
-$50 million (2020)
|
| gptkbp:partnerships |
gptkb:University_of_California,_San_Diego
gptkb:Cleveland_Clinic |
| gptkbp:patentCitation |
numerous patents in biotechnology
|
| gptkbp:researchFocus |
monoclonal antibodies
small molecules cell therapies |
| gptkbp:revenue |
$10 million (2020)
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:SRNE
|
| gptkbp:subsidiary |
Sorrento_Therapeutics_(China)_Co.,_Ltd.
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
www.sorrentotherapeutics.com
|